CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 409,900,000	$ 2,036,500,000
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	(36,600,000)	(9,100,000)
Net Cash Provided by (Used in) Financing Activities	(949,600,000)	(1,057,200,000)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net earnings	1,204,200,000	1,825,900,000
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation And Amortization Of Leased Assets	145,700,000	145,300,000
Depreciation and amortization	477,700,000	557,100,000
Stock compensation	113,900,000	111,600,000
Asset Impairment Charges	1,200,000	0
Deferred income taxes	(51,600,000)	(102,000,000.0)
Other Operating Activities, Cash Flow Statement	(4,900,000)	(41,000,000.0)
Change in assets and liabilities (net of effects of acquisitions):
Increase in accounts receivable (net)	(51,800,000)	(135,600,000)
Increase (Decrease) in Unbilled Contract Receivable	127,600,000	185,900,000
Increase in inventories	47,500,000	6,500,000
Decrease in accounts payable	135,100,000	34,600,000
Increase (Decrease) in Deferred Revenue	(10,700,000)	83,800,000
Increase (Decrease) in Prepaid Expense and Other Assets	67,800,000	72,400,000
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities	(517,200,000)	(74,000,000.0)
Net cash provided by operating activities	1,302,300,000	2,412,100,000
CASH FLOWS FROM INVESTING ACTIVITIES:
Cash payments for laboratory-related assets	(364,000,000.0)	(310,400,000)
Proceeds from sale of assets	1,200,000	3,500,000
Proceeds from Sale of Equity Method Investments	700,000	10,400,000
Payments to Acquire Equity Method Investments	(6,100,000)	(20,000,000.0)
Net Cash Provided by (Used in) Investing Activities	(1,378,900,000)	(630,100,000)
Payments to Acquire Businesses, Net of Cash Acquired	(1,013,600,000)	(326,000,000.0)
Net cash used for investing activities	(1,378,900,000)	(630,100,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments of Other Long-term Debt	0	375,000,000.0
Payment, Tax Withholding, Share-based Payment Arrangement	44,600,000	44,400,000
Net proceeds from issuance of stock to employees	50,600,000	50,800,000
Payments of Dividends	(131,600,000)	0
Payments for Repurchase of Common Stock	800,000,000.0	668,500,000
Other Financing Cash Flows	24,000,000.0	20,100,000
Net cash provided by (used for) financing activities	(949,600,000)	(1,057,200,000)
Repayments of Senior Debt	0	1,000,000,000
Proceeds from Issuance of Senior Long-term Debt	0	1,000,000,000
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	(1,062,800,000)	715,700,000
Cash and cash equivalents at beginning of period	1,472,700,000
Cash and cash equivalents at end of period	409,900,000
Business Acquisition [Line Items]
Proceeds from Sales of Business, Affiliate and Productive Assets	0	12,400,000
Proceeds from Hedge, Investing Activities	$ 2,900,000	$ 0